文献速递流行病学与生物统计医学教育与科研方法

多数非劣效性试验的设计未能保留阳性对照的治疗效应

Most noninferiority trials were not designed to preserve active comparator treatment effects.
PubMed 文献 · J Clin Epidemiol · 2019-03-08

该研究回顾了发表于高影响力医学期刊的162项非劣效性试验,评估其设计是否确保干预措施仅在保留阳性对照历史治疗效应至少50%时才能被判定为非劣效。结果显示仅25项(15%)试验满足这一设计标准,多数试验缺乏阳性对照有效的证据或非劣效性界值过宽,14项(9%)试验甚至允许干预措施劣于安慰剂或另一历史对照时仍被判定为非劣效。作者认为多数非劣效性试验可能导致错误的非劣效性声明。

要点

  • 仅15%(25/162)的非劣效性试验设计确保保留阳性对照历史效应至少50%。
  • 多数试验未提供阳性对照有效的证据(101项)或证据不充分(18项)。
  • 9%(14/162)的试验允许干预措施劣于安慰剂或历史对照时仍判定为非劣效。

核心结论

  • 发表于主要医学期刊的大多数非劣效性试验可能允许错误的非劣效性声明。

研究设计与样本

  • 回顾了162项发表于高影响力医学期刊的非劣效性试验,评估其设计是否确保干预措施仅在保留阳性对照历史治疗效应至少50%时才能被判定为非劣效。

主要发现

  • 仅25/162项试验(15%)的设计确保干预措施仅在保留阳性对照历史治疗效应至少50%时才能被判定为非劣效。
  • 101项试验未提供阳性对照有效的证据,18项试验提供的证据不充分,18项试验使用的非劣效性界值过宽。
  • 在61项引用了评估阳性对照的既往随机试验或Meta分析的非劣效性试验中,仅25项(41%)使用的非劣效性界值足够小以保留阳性对照治疗效应至少50%。
  • 14/162项非劣效性试验(9%)允许干预措施即使劣于安慰剂或另一历史对照时仍被判定为非劣效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate whether noninferiority trials are designed to adequately preserve the historical treatment effect of their active comparators. STUDY DESIGN AND SETTING: We reviewed 162 noninferiority trials published in high-impact medical journals. We assessed whether trials were designed to ensure that interventions could only be declared noninferior if they preserved at least 50% of the active comparator's historical treatment effect. RESULTS: Only 25 of 162 trials (15%) were designed so that interventions could only be declared noninferior if they preserved at least 50% of the active comparator's historical treatment effect. Most trials did not provide evidence that the active comparator was effective (n = 101), provided inadequate evidence (n = 18), or used a noninferiority margin that was too wide (n = 18). In a subset of 61 noninferiority trials which referenced a prior randomized trial or meta-analysis evaluating the active comparator, only 25 (41%) used a noninferiority margin small enough to preserve at least 50% of the active comparator's treatment effect. Overall, 14 of 162 noninferiority trials (9%) would have allowed the intervention to be declared noninferior even if it was worse than either placebo or another historical control. CONCLUSION: Most noninferiority trials published in major medical journals could allow erroneous declarations of noninferiority.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Tsui M, Rehal S, Jairath V, et al. Most noninferiority trials were not designed to preserve active comparator treatment effects. J Clin Epidemiol. 2019. PMID: 30858020. doi:10.1016/j.jclinepi.2019.03.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。